izpis_h1_title_alt

Coding of glioblastoma progression and therapy resistance through long noncoding RNAs
ID Zottel, Alja (Author), ID Šamec, Neja (Author), ID Videtič Paska, Alja (Author), ID Jovchevska, Ivana (Author)

.pdfPDF - Presentation file, Download (1,40 MB)
MD5: 579F23183B4293F463D342D164FCAB4C
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/12/7/1842 This link opens in a new window

Abstract
Glioblastoma is the most aggressive and lethal primary brain malignancy, with an average patient survival from diagnosis of 14 months. Glioblastoma also usually progresses as a more invasive phenotype after initial treatment. A major step forward in our understanding of the nature of glioblastoma was achieved with large-scale expression analysis. However, due to genomic complexity and heterogeneity, transcriptomics alone is not enough to define the glioblastoma "fingerprint", so epigenetic mechanisms are being examined, including the noncoding genome. On the basis of their tissue specificity, long noncoding RNAs (lncRNAs) are being explored as new diagnostic and therapeutic targets. In addition, growing evidence indicates that lncRNAs have various roles in resistance to glioblastoma therapies (e.g., MALAT1, H19) and in glioblastoma progression (e.g., CRNDE, HOTAIRM1, ASLNC22381, ASLNC20819). Investigations have also focused on the prognostic value of lncRNAs, as well as the definition of the molecular signatures of glioma, to provide more precise tumor classification. This review discusses the potential that lncRNAs hold for the development of novel diagnostic and, hopefully, therapeutic targets that can contribute to prolonged survival and improved quality of life for patients with glioblastoma.

Language:English
Keywords:glioblastoma, brain cancer, noncoding genome, biomarker, prognosis
Work type:Article
Typology:1.02 - Review Article
Organization:MF - Faculty of Medicine
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:22 str.
Numbering:Vol. 12, iss. 7, art. 1842
PID:20.500.12556/RUL-128766 This link opens in a new window
UDC:616-006
ISSN on article:2072-6694
DOI:10.3390/cancers12071842 This link opens in a new window
COBISS.SI-ID:22155779 This link opens in a new window
Publication date in RUL:28.07.2021
Views:807
Downloads:149
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:08.07.2020

Secondary language

Language:Slovenian
Keywords:glioblastom, možganski rak, nekodirani genom, biološki označevalec, prognoza

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0390
Name:Funkcijska genomika in biotehnologija za zdravje

Funder:ARRS - Slovenian Research Agency
Funding programme:Young Researcher Grant

Funder:ARRS - Slovenian Research Agency
Project number:Z3-1869
Name:Razvoj anti-FREM2 nanotelesa in njegova uporaba pri ciljanju glioblastomskih celic

Funder:EC - European Commission
Funding programme:Interreg
Project number:146
Acronym:TRANS-GLIOMA

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back